FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019

Abstract

This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.